Clinical Trial

Phase 1 Study of WBRT or PCSI With REYOBIQ for Leptomeningeal Metastases

Name: Phase 1 Study of WBRT or PCSI With REYOBIQ for Leptomeningeal Metastases — clinical trial record (NCT07674693)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This Phase 1 study is designed to assess the safety, tolerability, and schedule feasibility of administering Rhenium-186 NanoLiposome (REYOBIQ) at different dosing intervals following whole brain radiotherapy (WBRT) or proton craniospinal irradiation (PCSI).

Trial Details

NCT Number	NCT07674693
Lead Sponsor	NYU Langone Health
Conditions	Leptomeningeal Metastases
Enrollment	29 participants
Start Date	2026-07
Primary Completion	2028-07 (estimated)
Study Completion	2031-07 (estimated)
Updated on ClinicalTrials.gov	2026-06-29